
    
      This is an open label, balanced, randomized, two-treatment, two-period, two-sequence, single
      oral dose, crossover comparative Pharmacokinetics study of WD-1603 extended-release
      carbidopa/levodopa tablets in normal, healthy, adult human subjects under fasting conditions.
    
  